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Abstract
Schistosomiasis, caused mainly by S. mansoni, S. haematobium and S. japonicum, continues to be a serious tropical
disease and public health problem resulting in an unacceptably high level of morbidity in countries where it is
endemic. Praziquantel, the only drug currently available for treatment, is unable to kill developing schistosomes, it
does not prevent re-infection and its continued extensive use may result in the future emergence of drug-resistant
parasites. This scenario provides impetus for the development and deployment of anti-schistosome vaccines to be
used as part of an integrated approach for the prevention, control and eventual elimination of schistosomiasis. This
review considers the present status of candidate vaccines for schistosomiasis, and provides some insight on future
vaccine discovery and design.
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Background
The World Health Organization (WHO) considers
schistosomiasis to be second only to malaria as the most
devastating parasitic disease in terms of socioeconomic
importance and public health impact [1]. Human infec-
tion is due to three main species, namely Schistosoma
mansoni and S. japonicum which cause intestinal/hepatic
schistosomiasis [2, 3] and S. haematobium, which results
in urinogenital disease [4].
Human treatment with praziquantel (PZQ) is playing a
central role in the control and prevention of schistosom-
iasis, being the only effective drug currently available [5].
However, the drug does not prevent re-infection and its
exclusive use for the prevention and control of schisto-
somiasis is problematic; having been used for more than
three decades, the emergence of PZQ-resistant schisto-
somes is a constant threat. Other drawbacks with PZQ
are its poor activity against immature schistosomes,
resulting in sub-optimal outcomes during mass drug
administration campaigns and, as its mechanism of
action remains unclear, the design of alternative drug
formulations has proven difficult [5]. Furthermore, a
substantial infrastructure is required to ensure the drug
is supplied regularly in timely fashion to all parts of an
endemic area.
Originally used as a major preventative measure [6],
snail control, through the use of molluscicides (e.g.
niclosamide), is now not the recommended method in
isolation for the prevention of schistosomiasis [5]. In
order to control and finally eliminate schistosomiasis, a
vaccine will likely be a key component of an integrated
approach (i.e. involving mass chemotherapy, targeted
mollusciciding, environmental modification, health educa-
tion, improved sanitation and vaccination). A transmission
blocking vaccine for use in bovines could serve as a vital
component in the control of S. japonicum [7], whereas
clinical vaccines against S. mansoni and S. haematobium
need to be developed. However, it is a sobering thought
that no commercial vaccine is available currently against
any of the human schistosomes, thereby emphasising the
need for continued efforts towards achieving this goal.
This review evaluates the current status of schistosome
vaccine development.
Strategies for vaccine development
Although complex, the schistosome life-cycle, with its
various stages each expressing distinct antigens, provides
a vehicle for identifying many alternative molecules for
vaccine development. The fact that the different stages
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reside in different host niches (larvae in the skin and
lungs, adults in the liver and intestine or bladder capil-
laries) can help in the design of possible vaccines to pre-
vent the migration of schistosome parasites and their
maturation to adult worms. Importantly, the fact that
schistosomes do not replicate in the definitive host makes
partial reduction of the parasite burden sufficient to
control schistosomiasis, strengthening the argument for
developing an effective vaccine as a control intervention
[8]. When identifying a suitable vaccine candidate, it is
prudent to select key schistosome molecules in the live
parasite that are (a) exposed to the host immune system;
and (b) are essential for parasite survival. Such compo-
nents may, for example, function in migration, immune
evasion, nutrient uptake or attachment.
Adjuvant selection and mode of vaccine formulation
and delivery are other important considerations in
vaccine design and deployment as they can have a con-
siderable impact on the protective effectiveness of the
vaccine. It is well known that, in contrast to attenuated
cercarial vaccines, other types, such as subunit vaccines,
require an appropriate adjuvant to help stimulate the
immune system. A number of different adjuvants are
available such as gels, emulsions, particulates, cytokines,
microbial products (e.g. CpG, cholera toxin) and prote-
ases. Adjuvants can overcome immune senescence in
older individuals, prolong the immunological memory of
a vaccine, broaden the antibody repertoire and direct the
immune system to a Th1 biased, Th2 biased or mixed
Th1/Th2 biased response [9]. For example, a Th1 driving
adjuvant such as IL-12, administered with irradiated
cercariae, provided up to 90 % protection in murine
schistosomiasis [10, 11]. Currently, in order to increase
the protective efficacy of schistosome vaccines, a strategy
of combining existing adjuvants with novel ones, deve-
loped based on emerging immunological targets, has
been muted [11].
Some of the other challenges in schistosomiasis vaccine
development are the risk of an atopic IgE response to a
candidate vaccine [12], a lack in understanding of the
nature of the immune response and the correlates of
protective immunity in humans and other mammalian
hosts, the transmission of other pathogens in schistoso-
miasis endemic areas resulting in co-infected individuals
which can impact on vaccine efficacy, and antigenic poly-
morphism [13].
Schistosoma mansoni and S. haematobium vaccine
candidates
Over 100 schistosome vaccine antigens have been iden-
tified, of which about a quarter have shown some level
of protection in the murine model of schistosomiasis
[14]. Disappointingly, however, only three molecules,
S. mansoni fatty acid binding protein (Sm14), S. mansoni
tetraspanin (Sm-TSP-2) and S. haematobium glutathione
S-transferase (Sh28GST), have entered human clinical trials
with Smp80 (calpain) undergoing testing in non-human
primates [15].
A recent report has suggested that the murine model of
schistosomiasis may be intrinsically flawed for pre-clinical
testing of vaccine candidates as a result of the fragility of
the pulmonary capillaries in mice which can prevent mat-
uration of a large proportion of schistosome cercariae
upon challenge; this may lead to the incorrect assumption
that vaccine antigen-induced acquired protective immun-
ity has been generated [16]. This article has stimulated
vigorous debate and its conclusions require rigorous test-
ing but, with this caveat, some of the S. mansoni and S.
haematobium vaccine candidates that have been identified
are now highlighted below and in Table 1.
Sm14
Schistosomes lack an oxygen-dependent pathway for the
synthesis of sterols and fatty acids. Therefore, they are en-
tirely dependent on the mammalian host to provide these
essential lipids. Schistosomes use fatty acid binding pro-
teins (FABPs) to absorb, transport and compartmentalize
fatty acids from the host and, because of this critical bio-
logical function, Sm14 has long been considered a poten-
tial vaccine candidate [17]. Recombinant Sm14 (rSm14)
provided up to 67 % protection in terms of reduced
S. mansoni worm burden in outbred Swiss mice with-
out the use of an adjuvant, and encouragingly, no auto-
immune response was observed even though its structure
is identical in basic form with mammalian host homo-
logues [18]. It has been shown to be cross-species protec-
tive against both S. mansoni and Fasciola hepatica
infection. Development of a dual vaccine effective against
both fluke infections has great appeal in terms of human
and animal health. Recombinant Sm14 with glucopyra-
nosyl lipid adjuvant stable emulsion (GLA-SE) adjuvant
entered and successfully completed a phase 1 clinical trial
in healthy adult volunteers in Brazil, confirming its status
as safe and immunogenic [19]. Further immunogenicity
and safety phase 2 trials of rSm14 (adjuvanted with
GLA-SE) are planned for schistosomiasis-endemic areas
in Brazil and Africa [20].
Sh28GST
Schistosome 28 kDa glutathione S-transferase enzymes
play a role in fatty acid metabolism and prostaglandin
D2 synthesis and may help the parasite evade the host
immune system. The enzyme present in S. mansoni
(Sm28GST) has been tested extensively as a recombin-
ant protein vaccine in various experimental models and
has shown partial protection in terms of reduced worm
burdens, inhibition of female worm fecundity and a reduc-
tion in egg viability [21]. Along with Sm14, Sm28GST was
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Table 1 Recent data on Schistosoma mansoni vaccine candidates
Antigen Location in
adult worm
Identity/Function Immunization
strategy
Adjuvant Host Worm burden
reduction (%)
Liver egg burden
reduction (%)
Reference
Sm-p80 Associated with tegument
inner membrane
Calpain-neutral
cysteine protease
Recombinant protein Resiquimod Mouse 50 16 [25–30]
Primed with pcDNA3
and boosted with
recombinant protein
Resiquimod Mouse 49 30
Primed and boosted
with recombinant
protein
Oligodeoxynucleotide Mouse 70 75
Recombinant protein Resiquimod Baboon 58 –
DNA vaccine – Baboon 38–46 32–28
Fatty acid binding
protein (FABP) (Sm14)
Whole body, Cytosolic Absorbs, transports
and compartmentalizes
fatty acids from the host
Recombinant protein – Mouse 67 – [18]
Tetraspanin protein 2
(Sm-TSP2)
Tegument apical membrane Tetraspanin integral
membrane protein
Recombinant protein Freund’s Mouse 57 64 [99, 100]
Recombinant protein Alum/CpG Mouse 25 27
Glutathione S-transferase
(Sh28GST)
Whole body Enzyme involved in fatty
acid metabolism and
prostaglandin D2 synthesis
Recombinant protein Aluminium Baboon 0–80 – [101]
Sm29 Tegument apical membrane Unknown, but has a
C-terminal domain
DNA vaccine with
pUMVC3 plasmid
– Mouse 17–22 – [44, 102]
Recombinant protein Complete Freund’s
and Incomplete
Freund’s
Mouse 51 –
Sm14 + Sm-29 – – Multivalent
recombinant proteins
Poly (I; C) Mouse 40 68 [41]
Sm29 + Sm-TSP-2 – – Multivalent DNA
vaccine with pUMVC3
plasmid
– Mouse 24–32 – [43, 44]
Multivalent
Recombinant proteins
CpG-Alum Mouse 35 –
Oesophageal gland
secretion (Sm100.3)
Oesophagus Digestive tract proteins
(oesophageal)
Recombinant proteins Freund’s Mouse 25–32 33–44 [103]
Cathepsin B1(SmCB1) Gut (gastrodermis) Gut protease
(cysteine peptidase)
Recombinant proteins Postulated to have
inbuilt adjuvant
properties
Mouse 73 83 [104, 105]
(Combined with SG3PDHa
+ PRX-MAPb)
S. mansoni Cathepsin B
(Sm-CB)
Gut (gastrodermis) Gut protease
(cysteine peptidase)
Recombinant proteins CpG
oligodeoxynucleotides
Mouse 59 56
Montanide ISA 750 VG Mouse 60 62
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Table 1 Recent data on Schistosoma mansoni vaccine candidates (Continued)
Antigen Location in
adult worm
Identity/Function Immunization
strategy
Adjuvant Host Worm burden
reduction (%)
Liver egg burden
reduction (%)
Reference
Schistosome cysteine
proteinase, asparaginyl
endopeptidase (SmAE)
(Sm32)
Gut Gut protease
(Asparaginyl peptidase)
DNA vaccine – Mouse No significant
reduction
37 [106]
Lysosome-associated
membrane glycoprotein
(Sm-LAMP)
Gastrodermis Processing of ingested
blood
Recombinant protein alum-CpG Mouse 16–25 – [49]
Dynein light chain
proteins
Unknown Evolutionarily conserved
among different organisms
Recombinant protein Alhydrogel Mouse [52]
- DLC 12 43
- DLC 13 51
S. mansoni Syntenin
(SmSynt)
Intestinal tract Scaffold supporting
protein
Recombinant protein Complete and
incomplete Freund’s
Mouse 30–37 – [107]
Radiation-attenuated
cercariae
– – UV-attenuated – Mouse 43 73 [54]
Antioxidants
- Cu/Zn cytosolic
superoxide dismutase
– – DNA vaccine – Mouse 44–60 – [46, 47]
- signal peptide-containing
superoxide dismutase
– – DNA vaccine – Mouse 22–45
- glutathione peroxidase
enzymes
– – DNA vaccine – Mouse 23–55
Baboon 17.1
aGlyceraldehyde 3-phosphate dehydrogenase
bperoxiredoxin
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one of the six S. mansoni antigens originally indepen-
dently tested under the auspices of TDR/WHO [22]. The
S. haematobium homologue, Sh28GST (Bilhvax), formu-
lated with alum adjuvant, has undergone human clinical
trials [19, 23]. Cytokine production triggered by this
vaccine candidate was shown to be influenced by factors
such as host age, schistosome infection status and PZQ
treatment history and this has provided an indication as
to the features which should be considered for determi-
ning the efficacy of the GST-based vaccine during its
testing in targeted endemic communities [23]. The Phase
1 and 2 clinical testing showed Bilhvax was safe for healthy
and infected adults and children [13]. It was scheduled
to complete a phase 3 self-contained, randomized, double
blind clinical trial in 2012 (https://clinicaltrials.gov/ct2/
show/NCT00870649) evaluating whether co-administration
of the vaccine with PZQ could delay pathology relapse due
to S. haematobium infection in children. The trial results,
however, have yet to be released which has raised doubts
about the effectiveness of the vaccine.
Sm-p80
Calpain is a calcium activated neutral cysteine protease
[24]. Prime-boost vaccination (priming with DNA and
boosting with recombinant protein) with Sm-p80, the
large subunit of S. mansoni calpain, in combination with
resiquimod adjuvant, resulted in 49 % worm burden
reduction, while 50 % protection was achieved using
the recombinant protein as primary and boost vaccine
(immunized and then boosted by recombinant protein) in
mice [25]. With the same approach, but using a different
adjuvant, oligodeoxynucleotide (ODN) 10104, 70 % worm
burden reduction and 75 % egg reduction was achieved
with Sm-p80 [26]. Moreover, a 58 % worm burden reduc-
tion in baboons (Papio anubis) was reported recently with
the Sm-p80-based vaccine adjuvanted with resiquimod
and CpG ODN [27].
Using a different approach, a Sm-p80 DNA vaccine
conferred 59 % worm burden reduction and 84 % decrease
in egg production in mice [28]. In baboons the vaccine
provided levels of protection against S. mansoni infection
comparable to those achieved by the irradiated cercarial
vaccine; moreover, antibodies and IFN-γ were shown to
play an important role in the protective immunity gene-
rated in this non-human primate model [29, 30].
Importantly, recombinant Sm-p80 has also been shown
to exhibit cross-species protection against S. haemato-
bium in hamsters and baboons [31]. Promisingly, endu-
ring antibody titers were detected in mice at sixty weeks
post-vaccination with recombinant Sm-p80, and IgG
specific for Sm-p80 was detected in baboons 5–8 years
after initial vaccination with the Sm-80 DNA vaccine [32].
It is anticipated that the recombinant Sm-p80/GLA-SE
vaccine, “SchistoShield”, will move forward to phase 1 and
2 human clinical trials in 2017 [31, 32]. Furthermore,
it has also been shown that Sm-p80 has a therapeutic
effect in vaccinated baboons through decreasing the num-
bers of established worms, reducing the retention of eggs
in tissues, and decreasing the number of eggs excreted in
faeces [33].
Sm-TSP-2
The tetraspanins are a group of proteins that are highly
abundant in the schistosome tegument where they are
found at the outer-most membrane of the intra-mammalian
stage of the parasite, and hence are highly exposed to
the host immune system [34]. The major tetraspanin
proteins in S. mansoni are Sm-TSP-1 and Sm-TSP-2 with
the latter conferring protection in S. mansoni challenge
animal models and also correlating with protective
immunity in naturally resistant people [35]. Sm-TSP-2 is
currently being developed by the Sabin Vaccine Institute
Product Development Partnership as a 9 kDa recombinant
Sm-TSP-2/Alhydrogel® vaccine in combination with the
GLA-AF adjuvant; it has undergone toxicology studies
[36], has shown good preclinical results, expression of the
antigen can be readily scaled up [37] (http://www.sabin.org/
updates/pressreleases/phase-1-clinical-trial-sm-tsp-2-schis
tosomiasis-vaccine), and the vaccine has completed a phase
1 clinical trial although the outcome is not yet known.
Disappointedly, whereas high levels of IgG1 and IgG2 anti-
bodies were generated in mice against the recombinant
TSP-2 protein homologue from S. japonicum, no consistent
protective efficacy was achieved [38].
Sm29
Sm29 is present in the tegument of adult worms and
schistosomula and in its recombinant form it induces
high level production of IgG1 and IgG3 isotypes among
individuals resistant to infection and re-infection [39].
There are reports that recombinant Sm29 can prevent
infection in animals previously exposed to S. mansoni. For
example, 26–48 % protection was observed in BALB/c
mice that were previously infected with a Brazilian strain
of S. mansoni and treated with PZQ [40]. Recently an
increased level of protection was obtained through com-
bining Sm29 with Sm14 in the presence of poly I:C
adjuvant; 40.3, 68.2 and 57.9 % reductions in adult worm
burden, liver egg burden and intestinal eggs, respectively,
was achieved, along with a reduction in granuloma size
and number in the livers of immunized mice [41].
Another report showed that by fusing Sm29 and Sm14, a
48.4 % reduction in adult worm burden in mice was
achieved [42]. Similarly, fusing Sm29 with Sm-TSP-2
resulted in an increased reduction (from 22 to 35 %) in
the number of worms, a higher titre of IgG1 and IgG2
antibodies and increased levels of IFNγ and TNFα than
Sm29 alone in challenged mice [43, 44]. In a further
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advance, recombinant Sm29 was subjected to high hydro-
static pressure which dissociated the aggregated protein
resulting in a successfully folded, soluble, stable and struc-
tured molecule produced in high yield, which was protec-
tive against S. mansoni, thereby paving the way for its
industrial production down track [45].
Antioxidants
The antioxidants Cu–Zn superoxide dismutase (SOD)
and glutathione S peroxidase (GPX) induced greater than
40 % reduction in worm burdens when administered
as DNA-based vaccines in S. mansoni-challenged mice
[46]. Similarly, a recent study showed a protective effect
against schistosomiasis in baboons [47]. These non-human
primates, vaccinated with two different formulations of
SOD (SmCT-SOD and SmSP-SOD) and one of GPX, with
a protocol of priming with naked DNA and boosting with
the respective recombinant antioxidant proteins encap-
sulated in polylactic acid (PLA) microspheres, exhibited a
robust immune response, which resulted in a reduction in
worm numbers, and a pronounced anti-pathology effect
compared with control animals [47].
Digestive tract proteins
Schistosoma mansoni worms ingest host blood which
passes through the oesophagus before arriving at an area
in the gut where many peptidases catalyse its proteolysis.
The processing of the blood and the resulting uptake of
nutrients are functions essential for the survival of
the parasite. Blocking these critical processes represents an
important strategy for vaccine development and a number
of digestive tract proteins, that are not recognized by host
immune responses during normal infection, but are essen-
tial for parasite survival, have been tested as cryptic vaccine
candidates [48]. One example was the trialling of a soluble
form of schistosome lysosome-associated membrane glyco-
protein (Sm-LAMP), located in the gastrodermis, which
resulted in a reduction in worm burden (16–25 %) and in
faecal eggs (52–60 %); moreover, its insoluble form pro-
duced up to 38 % reduction in liver egg burden [49].
Another recent study identified a number of esophageal
secreted proteins, encoded by microexon genes (MEGs),
that are involved in the initial processing of ingested blood
and these, along with lysosomal hydrolase, also localised
to the oesophagus, may prove to be novel immune targets
[50]. Other examples of digestive proteins as potential vac-
cine targets are described in Table 1 and elsewhere [51].
DLC/LC8
Proteins with the dynein light chain family (DLC/LC8)
domain, which is evolutionarily conserved in different
organisms, have been considered recently as vaccine tar-
gets against schistosomiasis as some homologues, such as
the TAL family (Tegumental Allergen Like), are present in
the distal cytoplasm of cells, in the tegument and on the
membranous surface of schistosomes [52]. Recombinant
S. mansoni DLC 12 and DLC 13, adjuvanted with alhy-
drogel, demonstrated a 43 and 51 % reduction in worm
burdens respectively, in vaccinated and challenged mice
[52]. Furthermore, both DLCs reduced the size of granu-
lomas in hepatic tissues by up to 70 %. Their encouraging
immunogenicity and protective efficacy, coupled with the
absence of any allergic reactivity, warrants their further
study as individual vaccine antigens or as part of a multi-
component vaccine [52]. As DLC proteins are associated
with motor myofibrillar proteins with intracellular function,
the mechanism by which DLC immunization conferred
protection remains to be determined.
Attenuated S. mansoni vaccines
Schistosoma mansoni cercariae, attenuated by heat,
chemical or ultraviolet treatment, or by ionizing radi-
ation (gamma or X-ray), have been shown to provide
protection against S. mansoni challenge in several mam-
malian species [24, 53]. Recent studies undertaken with
UV-radiation-attenuated cercariae given once or, more
effectively, multiple times to C57BL/6 mice have confirmed
earlier findings with significant reductions in worm and
hepatic and intestinal egg numbers in vaccinated animals
[54, 55]. Moreover, tegumental changes in the adult worms
(swelling, fusion of tegumental folds, vesicle formation and
loss or shortening of spines on the tubercles) were evident
[54, 55].
A recent systematic meta-analysis and review of the
available publications in the area on mice indicated the
irradiated cercarial vaccine has the potential to achieve
protection as high as 78 % with one vaccination dose [53].
Although the models showed the generated protection
waned, it remained elevated for at least eight months after
vaccination, reinforcing the view that the level of protec-
tive immunity obtained, although partial, would reduce
both schistosome transmission and parasite-associated
morbidity [53]. This re-emphasises the potential of deve-
loping an attenuated cercarial vaccine, a concept proposed
some years back that might well be worth revisiting
[56], with the caveat that it would in all likelihood be
problematical for human use (perhaps less so for appli-
cation in reservoir hosts of S. japonicum), since such an
attenuated vaccine would, for example, likely carry too
high a risk of side effects or of partially or unattenuated
parasites reaching the mesenteric veins and becoming
patent. Long-term storage of such a vaccine before deploy-
ment is another challenge that would need to be overcome.
Vaccine candidates for S. japonicum
Whereas clinical vaccines will need to be developed against S.
haematobium and S. mansoni, the zoonotic nature of schis-
tosomiasis japonica allows for a complementary approach
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for S. japonicum involving a transmission blocking vaccine
for livestock animals, particularly bovines [24]. The vaccine
would be used in reservoir hosts of S. japonicum to reduce
transmission to humans [24].
Attenuated S. japonicum vaccines
Vaccination of bovines with gamma irradiated schistoso-
mula resulted in a significant reduction in adult worms
and liver eggs compared with control animals [57].
Moreover, vaccination of pigs using UV-attenuated
cercariae, produced variable, although highly promising,
levels of protection in terms of reduced adult worms
and hepatic egg burden in animals receiving a single
immunization or those vaccinated three times [58]. The
protective response was shown to be associated with IFNγ
and IgG2 antibody production [59]. A pilot study in mini-
ature pigs, using similar methodology (but incorporating
a lower number of challenging cercariae), resulted in more
than 80 % worm reduction [60]. However, it has been
reported that unstable and relatively low protection is
induced in C57BL/6 mice by attenuated S. japonicum
cercariae. This is likely due to the poor Th1 response
generated and the less robust antibody response produced
in comparison with BALB/c mice, and suggests this
mouse strain might be a sub-optimal model for studying
the mechanisms of immune protection against this schis-
tosome species [61].
Sj97
Paramyosin is a myofibrillar 97 kDa protein present in the
muscle layers and the tegument of schistosomes that has
long been regarded as a vaccine candidate against S.
japonicum and S. mansoni infection [24]. An early study
showed that mice vaccinated intraperitoneally with
purified paramyosin (without the use of an adjuvant)
stimulated 62–86 % resistance against S. japonicum
cercarial challenge [62]. In addition to preventing infec-
tion, a longitudinal treatment-re-infection design study in
Leyte, the Philippines showed that a Th2 bias in response
to Sj97 predicted a longer time to human re-infection and
a lower re-infection intensity after treatment with PZQ
[63, 64]. Moreover, it was reported in the human Leyte
cohort that individuals who produce IgE but not IgG4 in
response to rSj97 had 77 % lower re-infection intensity
after 12 months >of treatment with PZQ [64, 65]. Sj97 is
now in early preclinical testing with process development
and further proof of concept studies taking place in mice
and water buffalo [13, 64].
Sj26GST
A S. japonicum 26 kDa GST plasmid DNA vaccine
(Sj26GST) resulted in a significant reduction in worm
numbers and in hepatic and faecal eggs in vaccinated
mice; when the DNA vaccine was given in combination
with interleukin 18 (IL-18), a potent IFN-γ inducing
factor, the protective efficacy was improved [66]. DNA
vaccines have some advantages over other types of
immunization but they have some limitations concer-
ning the gene delivery system. A recent study reported
on a novel nanoparticle formulation of the Sj26GST
DNA vaccine; although there was no significant reduc-
tion in worm burden, a highly significant decline in
tissue egg burden and the fecundity of female adult
worms resulted [67]. Toll-like receptor (TLR) 7/8 ligands
(e.g. R848) and TLR 9 ligands (e.g. CpG oligodeoxy-
nucleotides, or CpG) as adjuvants can increase vaccine
effectiveness through activating the innate immune sys-
tem and ultimately activating and directing the adaptive
immune system. Such adjuvants have been shown to
potentiate the activity of the Sj26GST DNA vaccine in
mice by increasing splenocyte proliferation, elevating
IgG, IgG2a, IFNγ and TNFα levels, and preventing
Treg-mediated immunosuppression [68]. In another
development, Sj26GST alone, or in combination with fatty
acid binding protein (SjFABP), expressed in recombinant
pseudorabies virus (PRV) Bartha-K61, induced significant
levels of specific immunity and protection in mice and,
importantly, sheep, emphasising the potential effectiveness
of this live vector for vaccination against schistosomiasis
japonica in animal reservoirs [69].
SjTPI
The glycolytic pathway enzyme triose-phosphate isome-
rase (TPI), found in all stages of the schistosome life-cycle,
is another targeted vaccine candidate for schistosomiasis
japonica. An early study showed that a S. japonicum
(Chinese strain) TPI (SjCTPI) plasmid DNA vaccine (with
or without an IL-12 DNA plasmid) protected pigs against
challenge infection [70]. Synergistic enhancement of im-
munogenicity and protection in mice against S. japonicum
challenge was achieved with codon optimization and elec-
troporation delivery of the SjTPI DNA vaccine [71], show-
ing a similar level of protection as a replication-defective
recombinant optimized SjTPI (rAdV-SjTPI) adenoviral
vaccine [72] which was enhanced using a heterologous
prime-boost strategy [73]. A study, conducted in Chinese
water buffalo with a DNA vaccine encoding SjCTPI alone
or fused with bovine HSP-70 with booster immunizations
co-administered using a plasmid encoding IL-12, resulted
in a significant reduction in worm numbers, liver and
faecal eggs and in faecal miracidial hatching [74]. SjCTPI,
delivered by a heterologous “prime-boost” regimen, has
been used to vaccinate bovines in China as part of a
multi-component integrated control package [75].
SjIRs
Schistosoma japonicum possess two types of insulin recep-
tors (SjIRs) which, on binding to mammalian host insulin,
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can activate the parasite’s insulin pathway, which is pivotal
for glucose uptake, growth, and maturation [76]. Recom-
binant ligands of both S. japonicum insulin receptor 1 and
2 (SjLD1, SjLD2), tested in vaccine/challenge trials in mice
resulted in significant reductions in faecal egg output, in
reduced mature intestinal eggs and stunting of adult
worms [77, 78]. The retardation in growth of the worms
likely resulted from reduced glucose uptake [77]. Further-
more, knockdown of the SjIRs using RNA interference
(RNAi) resulted in their reduced expression coupled with
a reduction in the transcription level of downstream genes
within the insulin pathway that are associated with
glucose metabolism and schistosome fecundity [79],
thereby reinforcing their vaccine potential.
Sj14
In early studies, Sj14 (fatty acid binding protein;
SjFABP), the S. japonicum homologue of Sm14, gene-
rated no or only a limited level of protection [24], but
when given to mice as a DNA vaccine with a plasmid
coding for IL-18 as adjuvant, the level of protection
was increased substantially [80]. The latter study also
showed that SjFABP + IL-18 increased the Th1 immune
response by producing a higher level of IFNγ and a lower
level of IL-4 compared with mice vaccinated only with
SjFABP [80]. Somewhat disappointedly, the Sj14 DNA
vaccine, coupled with Sj26GST to form a bivalent DNA-
based vaccine, resulted in a reduced level of protective
efficacy [81].
Sj23
Sj23, like Sm-TSP-2, a member of the tetraspanin family,
is a 23-kDa surface-exposed integral membrane protein
expressed in all infective parasite stages. It was shown in
BALB/c mice to elicit a rapid humoral immune response
dominated by IgG2a antibodies, but not IgG1, and did
not provide protection against cercarial challenge after
priming with recombinant Semliki forest virus (SFV)
particles followed by a boost with recombinant protein
[82]. A subsequent report of mice vaccinated with
purified recombinant protein LHD-Sj23-GST (large hydro-
philic domain of Sj23 fused with Sj26GST) in combination
with one of three adjuvants (Freund’s adjuvant (FA),
Montanide ISA 206 or Montanide ISA 70 M), and parasite
challenged, resulted in high-level production of LHD-
Sj23-GST-specific IgG1, IgG2a and IgG3 antibodies and
significant reductions in worm burden [83]. In order to
further improve on the level of protection, a multivalent
DNA vaccine comprising Sj23, glyceraldedyde-3 phos-
phate dehydrogenase (SjGAPDH), SjFABP and Sj26 was
tested in mice which resulted in very high levels of pro-
tective efficacy in terms of reduced worms (70.8 % reduc-
tion) and liver eggs (60.7 % reduction) [84]. Another study
in mice, using three cocktail DNA vaccines encoding Sj23,
SjCTPI and NP30, boosted by electroporation in vivo and
a protein vaccine boost to this regimen, resulted in a 60 %
reduction in adult worm numbers and more than 60 %
reduction in the liver egg burden [85].
Details of these and a number of other vaccine candi-
dates tested against S. japonicum challenge infection are
presented in Table 2 and elsewhere [78].
New antigen discovery: a way forward
New antigen discovery has been aided by major recent
advances in schistosome genomics, transcriptomics and
post-genomic technologies [86]. Proteomics is another
important and now widely used tool that can identify
potential vaccine targets with a focus on the protein
constituents of different schistosome sources such as the
host-parasite interface comprising tegument or gut [87].
Studies on the tegument have used a number of pro-
cedures including biotin-labelling of live parasites and
subsequent isolation and characterisation of the biotinyl-
ated proteins using tandem mass spectrometry (MS/MS)
to identify surface-located proteins, and therefore those
accessible to host antibodies. Proteomics of the schisto-
some gut and its contents has shed new light on the
functionality of this important region of the parasite
[87]. Coupled with other approaches such as metabo-
lomics, interrogation of the schistosome proteome, par-
ticularly the surface, provides a mechanism to identify
important clinically-relevant proteins and those having
potential as new vaccine targets [87].
Vaccinomics is another powerful innovation which
provides a foundation for searching critical determinants
of immunity and can promote antigen discovery and the
design of novel vaccines for complex pathogens such as
the schistosomes [88]. A recent vaccinomics approach
for discovering novel schistosome antigens that may not
be revealed by conventional proteomics involved the
design and manufacture of an immunomics protein
microarray, the first to be generated for a multi-cellular
pathogen. Mostly surface-derived proteins (215 in total)
from S. japonicum and S. mansoni were selected and they
were produced using a rapid in vitro translation system,
and then printed as a vaccine discovery tool [87, 89, 90].
The reactivity of microarray proteins can be measured
with antisera from human patients or schistosomiasis-re-
sistant/exposed animals using a labelled secondary
antibody and a laser microarray scanner; highly reactive
proteins are then assessed as putative vaccines.
One application of the array used antibodies from
acutely- or chronically-infected Chinese individuals with
early/advanced schistosomiasis japonica, and subjects
exposed, but stool negative for S. japonicum eggs, for
screening. This resulted in the identification of 25 immu-
nodominant antigens, including a number of vaccine
candidates, transporters, tetraspanin-related proteins, and
Tebeje et al. Parasites & Vectors  (2016) 9:528 Page 8 of 15
Table 2 Recent data on Schistosoma japonicum vaccine candidates
Antigen Location in
adult worm
Identity/Function Immunization
strategy
Adjuvant Host Worm burden
reduction (%)
Liver egg burden
reduction (%)
Reference
Paramyosin (sj97) Schistosomulum
surface, tegument
and acetabular glands
Binds complement
and Fc region of IgG;
proposed role in host
immune evasion
Recombinant
proteins
Alum or
TiterMax
Pig 33–34 – [108]
Sj26GST Parenchymal region
of male worm and in
the parenchymal cells
between the vitelline
glands in the female
worm
Catalyses detoxification
of lipophilic molecules
by thioconjugation
DNA vaccine – Mouse 30 45 [66, 69, 109]
26-kDaGST + IL-18 – – DNA vaccine – Mouse 49 51
SjGP-3 (Sj26GST + PmyF3
(fragment of paramyosin))
– – Polyvalent
subunit
CFA Mouse 41–38 26–29
rPRV/Sj26-KDaGST+ SjFABP – – Recombinant
pseudorabies
virus
– Mouse 39 45
Sheep 48 51
Triose phosphate isomerise
(SjTPI)
– Glycolytic pathway
enzyme
[71–74]
- with codon optimiized
version
DNA vaccine – Mouse 50 57
- with SjTPI + heat-shock
protein 70
DNA vaccine – Water buffalo 52 61
- with recombinant
replication-defective
adenoviral vectors
Replication
defective
adenoviral
vector-based
– Mouse 54 52
- with prime-boost strategy Adenoviral
vectored prime
and recombinant
protein boost
Complete
Freunds and
Incomplete
Freunds
Mouse 72 72
Thyroid hormone receptor
beta (SjTHRβ)
– Interacts with thyroid
hormone to modulate
growth, development
and differentiation, and
metabolic processes
Recombinant
protein
Montanide
ISA 206
Mouse 27 29 [110]
S. japonicum fatty acid
binding protein (SjFABP)
Whole body, cytosolic Uptake, transports and
compartmentalizes the
fatty acids of the host
DNA vaccine – [80, 81]
- with IL-18 Mouse 38 45
- with Sj26GST Mouse 32 25
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Table 2 Recent data on Schistosoma japonicum vaccine candidates (Continued)
Antigen Location in
adult worm
Identity/Function Immunization
strategy
Adjuvant Host Worm burden
reduction (%)
Liver egg burden
reduction (%)
Reference
Twenty-three kilo
dalton integral
membrane protein
(Sj23) with different
adjuvants
Surface-exposed Facilitates parasite
immune regulation
Recombinant
protein
Freunds Mouse 59 – [83]
ISA206 Mouse 26 –
ISA70M Mouse 54 –
Tetravalent DNA
vaccine (SjFABP.
Sj23/Sj26.SjGAPDH)
– – DNA vaccine – Mouse 71 61 [84]
Cocktail DNA with
EP and protein vaccines
(Sj23+ SjCTPI+ CDR3)
– – DNA vaccine
boosted with
recombinant
protein
Complete
Freunds
Mouse 59 67 [85]
Protein disulfide (SjPDI)
isomerase
Tegument as well as
other specialized
excretory/secretory
(ES)organs
Enzyme involved in
disulfide bond formation
and rearrangement and
it interfere with the host
immune
Recombinant
protein
Montanide
ISA 206 VG
Mouse 38 33 [111]
Responses
S. japonicum inhibitor
apoptosis protein using
adenovirus as live
vaccine vector (Ad-SjIAP)
Involved in differentiation
and development
With
recombinant
adenoviral vector
– Mouse 38 32 [112]
Aldose reductase (SjAR) Gynecophoral canal of
adult male worms
Involved in antioxidant
defence system
Recombinant
protein
Freunds Mouse 33 28 [113]
S. japonicum Sj-F1
(using S. gordonii as live
vector) (Sj-F1)
Gene discovered when
adult S. japonicum worm
cDNA library was screened
with by serum prepared
against female S. japonicum
antigens
Unknown With S. gordonii
as live vector
– Mouse 21 35 [114]
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unannotated proteins [91]. The array has also been
screened for IgG subclass and IgE responses, using sera
from a human Brazilian cohort of putatively resistant
(PR) and chronically S. mansoni-infected (CI) individuals
stratified by worm intensity levels (high, medium, low),
determined by faecal egg counts, so as to identify antibody
signatures reflective of protective vs non-protective
immune responses [92]. Probing for IgE responses
allowed the identification of antigens that might induce
potentially deleterious hypersensitivity reactions if used as
subunit vaccines in endemic populations so it was encou-
raging that the PR individuals did not mount an in-
tense IgE response to these antigens compared with CI
subjects [92].
This immunomics-based approach to schistosomiasis
vaccine antigen discovery was further validated by the
identification of targets of the protective IgG1 immune
response in PZQ-induced resistant subjects exposed
to S. haematobium; uncharacterized proteins and a num-
ber of recognised vaccine antigens (e.g. glucose trans-
porters, tetraspanins, glutathione-S-transferases, calpain)
were identified [93]. The same report described the use
of sera from rhesus macaques experimentally rendered
resistant to S. japonicum infection to screen for antigen
targets, and the discovery of new and known vaccine
candidates, including many recognized by the human
subjects.
Another important application has been the immune
screening of the schistosome microarray with antibody
secreting cell (ASC)-probes [89, 90, 94], generated from
lymph nodes draining the sites of larval S. japonicum
migration [95]. This technique is especially advanta-
geous for recognizing antigens with low immunogenicity
(selective pressure may have an influence on important
protective epitopes which evolve over time with low
immunogenicity) or those only temporarily exposed to the
immune response [90]. In one study, ASC probes (from
skin and lung) and sera from semi-permissive rats and
sera from susceptible mice were used to screen the array
after infection and re-infection with S. japonicum [94].
A total of 29 antigens, including a number of recognised
vaccine candidates and several S. japonicum homologues
of human schistosomiasis resistance markers - the tegu-
ment allergen-like proteins - were differentially recognized
by infected hosts from which eight proteins were priori-
tized as putative novel schistosome vaccine and diagnostic
antigens [94]. In a related study, the protein microarray,
screened with ASC probes generated from S. japonicum-
infected rats, resulted in the identification of a novel anti-
gen, termed S. japonicum Ly-6-like protein 1 (Sj-L6L-1)
which shares structural and sequence features with the
Ly-6 protein family and has several other features sugges-
ting it is a promising vaccine candidate against the deve-
loping larvae [96].
Conclusion
Schistosomiasis remains a substantial public health pro-
blem due to the very high levels of morbidity it causes in
many parts of the world. Currently, treatment is entirely
dependent on PZQ chemotherapy. As exclusive use of the
drug may lead to the emergence of drug resistant strains,
development and deployment of a vaccine as part of an
integrated approach for prevention and control of schis-
tosomiasisis is to be encouraged. Much of our current
understanding of immunity and immune mechanisms
against schistosomiasis rely on studies conducted on mice,
but vaccines based on studies performed only in the
mouse model could have undesirable effects if taken pre-
maturely to human clinical trials. The recent concern
raised about using mice for determining the efficacy of
vaccine candidates further reinforces the argument that
additional critical examination of any identified candidate
vaccine antigen, whether or not it has foundation in
acquired immunity is essential, and that moving to studies
using larger models such as rabbits, pigs or bovines in
the case of S. japonicum, or non-human primates for
S. mansoni and S. haematobium, is clearly necessary. Fur-
thermore, much of our knowledge regarding immune pro-
tection has resulted from studies focused on S. mansoni,
so further studies on S. japonicum and, particularly, S.
haematobium are needed. Similarly, protection levels of
many candidate vaccines show improvement after modi-
fication of antigen formulation and improved delivery
systems. Combining different genes or antigens can also
result in higher levels of vaccine-induced protection.
Targeting key biological functions of schistosomes such as
tegumental integrity, fecundity, and nutrient uptake using
RNAi represent key potential sites to target the parasites
for elimination through vaccination [97]. Although in
its infancy, CRISPR technology may provide a novel
approach identifying specific protein-encoding schis-
tosome genes for vaccine candidate discovery [98].
Schistosomiasis vaccine development has proven highly
challenging and costly and new funding is required to pro-
mote the generation of a schistosome vaccine antigen
pipeline, similar to that in place for many other infectious
diseases, and to progress existing promising candidates
into clinical trials. It is becoming apparent that mass drug
administration alone will not eliminate schistosomiasis
and that a vaccine will be an essential component of any
future schistosomiasis control intervention toolbox.
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